CorMedix Inc. (CRMD) Financial Ratios
18 years of historical data (2008–2025) · Healthcare · Biotechnology
EV/EBITDA
3.78
↓-33% vs avg
5yr avg: 5.67
30Y Low5.7·High5.7
P/FCF
3.60
↓-33% vs avg
5yr avg: 5.41
30Y Low5.4·High5.4
P/B Ratio
↓
1.57
↓-52% vs avg
5yr avg: 3.30
30Y Low1.9·High11.3
ROE
↑
66.6%
↓+349% vs avg
5yr avg: -26.8%
30Y Low-158%·High67%
Debt/EBITDA
0.90
+0% vs avg
5yr avg: 0.90
30Y Low0.9·High0.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CRMD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
CorMedix Inc. trades at 3.9x earnings, 32% below its 5-year average of 5.7x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a discount of 83%. On a free-cash-flow basis, the stock trades at 3.6x P/FCF, 33% below the 5-year average of 5.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $621M | $934M | $477M | $191M | $170M | $171M | $212M | $176M | $115M | $28M | $58M |
| Enterprise Value | $624M | $937M | $437M | $148M | $127M | $119M | $171M | $159M | $103M | $17M | $50M |
| P/E Ratio → | 3.88 | 5.70 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.99 | 3.00 | 10.97 | — | 2598.42 | 897.58 | 887.07 | 620.71 | 267.38 | 83.72 | 259.21 |
| P/B Ratio | 1.57 | 2.30 | 5.63 | 2.73 | 3.09 | 2.73 | 4.80 | — | — | — | 3.26 |
| P/FCF | 3.60 | 5.41 | — | — | — | — | — | — | — | — | — |
| P/OCF | 3.55 | 5.34 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CRMD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
CorMedix Inc.'s enterprise value stands at 3.8x EBITDA, 33% below its 5-year average of 5.7x. The Healthcare sector median is 14.4x, placing the stock at a 74% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.01 | 10.05 | — | 1947.55 | 623.18 | 716.22 | 562.39 | 240.62 | 52.20 | 223.22 |
| EV / EBITDA | 3.78 | 5.67 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 4.16 | 6.24 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 5.42 | — | — | — | — | — | — | — | — | — |
CRMD Profitability
Margins and return-on-capital ratios measuring operating efficiency
CorMedix Inc. earns an operating margin of 48.2%. Operating margins have expanded from -51.4% to 48.2% over the past 3 years, signaling improving operational efficiency. Return on equity of 66.6% is exceptionally high. ROIC of 49.7% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.5% | 88.5% | 92.7% | — | 94.3% | 22.0% | 14.4% | -31.8% | 7.7% | 65.1% | -63.6% |
| Operating Margin | 48.2% | 48.2% | -51.4% | — | -46819.9% | -15417.5% | -11378.4% | -7416.3% | -6250.4% | -9997.4% | -11048.8% |
| Net Profit Margin | 52.3% | 52.3% | -41.2% | — | -45409.9% | -14774.7% | -9207.7% | -5801.3% | -6242.4% | -10023.4% | -10996.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 66.6% | 66.6% | -23.2% | -74.0% | -50.4% | -52.7% | -49.8% | — | — | — | -95.1% |
| ROA | 34.5% | 34.5% | -17.8% | -64.3% | -45.4% | -47.7% | -55.9% | -68.0% | -166.2% | -186.7% | -83.5% |
| ROIC | 49.7% | 49.7% | -46.8% | -185.2% | -200.7% | -321.0% | -609.4% | — | — | — | -116.3% |
| ROCE | 40.8% | 40.8% | -28.7% | -77.5% | -51.3% | -54.1% | -79.1% | -121.1% | -294.4% | -263.3% | -95.5% |
CRMD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
CorMedix Inc. carries a Debt/EBITDA ratio of 0.9x, which is very conservative (73% below the sector average of 3.3x). Net debt stands at $3M ($149M total debt minus $146M cash). Interest coverage of 54.0x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.37 | 0.37 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | — | — | — | — |
| Debt / EBITDA | 0.90 | 0.90 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.01 | -0.47 | -0.61 | -0.77 | -0.83 | -0.92 | — | — | — | -0.45 |
| Net Debt / EBITDA | 0.02 | 0.02 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 0.02 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 53.97 | 53.97 | -529.83 | — | -1141.27 | -1846.86 | -817.55 | -26.68 | -14323.42 | -5873.70 | -18797.58 |
CRMD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
CorMedix Inc.'s current ratio of 2.01x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 6.97x to 2.01x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.01 | 2.01 | 3.39 | 6.97 | 9.44 | 12.44 | 11.58 | 5.04 | 2.40 | 2.12 | 5.34 |
| Quick Ratio | 1.84 | 1.84 | 3.16 | 6.78 | 9.44 | 12.43 | 11.54 | 4.98 | 2.35 | 2.02 | 5.29 |
| Cash Ratio | 0.86 | 0.86 | 1.53 | 6.67 | 9.35 | 12.25 | 11.14 | 4.89 | 2.27 | 1.91 | 4.93 |
| Asset Turnover | — | 0.38 | 0.37 | — | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.02 | 0.01 |
| Inventory Turnover | 1.21 | 1.21 | 0.42 | 0.10 | — | 49.51 | 1.43 | 1.10 | 0.93 | 0.19 | 2.20 |
| Days Sales Outstanding | — | 200.51 | 433.69 | — | — | 86.73 | 5.12 | — | 9.26 | 71.10 | 19.57 |
CRMD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
CorMedix Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 25.8% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 25.8% | 17.5% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 27.8% | 18.5% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $80M | $59M | $51M | $40M | $38M | $29M | $24M | $18M | $11M | $8M |
Peer Comparison
Compare CRMD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CRMDYou | $621M | 3.9 | 3.8 | 3.6 | 88.5% | 48.2% | 66.6% | 49.7% | 0.9 |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 SUPN | $3B | -76.9 | 53.4 | 65.5 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 PCRX | $930M | 147.8 | 9.9 | 6.8 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 AVNS | $1B | -17.0 | — | 26.9 | 49.8% | -8.8% | -8.5% | -5.4% | — |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 MASI | $9B | -63.8 | 27.7 | 47.3 | 61.9% | 20.5% | -17.1% | 16.5% | 1.6 |
 ANGO | $469M | -13.6 | — | — | 53.9% | -13.7% | -17.5% | -22.9% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 18 years · Updated daily
See CRMD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRMD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CRMD vs NKTR
Side-by-side business, growth, and profitability comparison vs Nektar Therapeutics.
Start ComparisonCRMD — Frequently Asked Questions
Quick answers to the most common questions about buying CRMD stock.
What is CorMedix Inc.'s P/E ratio?
CorMedix Inc.'s current P/E ratio is 3.9x. The historical average is 5.7x.
What is CorMedix Inc.'s EV/EBITDA?
CorMedix Inc.'s current EV/EBITDA is 3.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 5.7x.
What is CorMedix Inc.'s ROE?
CorMedix Inc.'s return on equity (ROE) is 66.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -68.4%.
Is CRMD stock overvalued?
Based on historical data, CorMedix Inc. is trading at a P/E of 3.9x. Compare with industry peers and growth rates for a complete picture.
What are CorMedix Inc.'s profit margins?
CorMedix Inc. has 88.5% gross margin and 48.2% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does CorMedix Inc. have?
CorMedix Inc.'s Debt/EBITDA ratio is 0.9x, indicating low leverage. A ratio below 2x is generally considered financially healthy.